

16310 U.S. PTO



111903

PATENT

Docket No. FWLPAT013US

031088 U.S. PTO
10/716981



Commissioner for Patents
Mail Stop Patent Application
P.O. Box 1450
Alexandria, VA 22313-1450

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of

Inventor: **Binie V. Lipps, Frederick W. Lipps**

For (title): **SYNTHETIC PEPTIDE FOR NEUROLOGICAL DISORDERS**

1. Type of Application--Continuation Application

Remarks

This new application is a continuation application. The parent application is application number 09/613,355 filed July 11, 2000, and assigned to Examiner Sharon Turner in AU 1647. A two month extension of time is being filed under separate cover in the parent application, this continuation application being the responsive action.

This application has been amended from that originally filed by the addition of a cross-references section to page 1, by amendment to the description to comply with the requirements for applications containing sequences--such amendments having previously entered in the parent application, and by amendment to the abstract of the disclosure to comply with requirements for abstracts, such amendment also previously have been entered in the parent application. No new matter is presented.


CERTIFICATION OF EXPRESS MAILING DATE

I hereby certify that this correspondence is being deposited by me with the United States Postal Service on 19 Nov 2003 in an envelope as "Express Mail, Post Office to Addressee",

bearing Label Number ER494266442 US, addressed to the above addressee.

Date

11-19-03


John R. Casperson Reg. No. 28, 198

Send correspondence to:

John R. Casperson
PO Box 2174
Friendswood, Texas 77549

Remarks--continued

The sequence listing differs from that originally filed and as subsequently amended in the parent application in that it was produced using PatentIn 3.1 and it does not contain a field <223> ISOLATE FROM VENOM pertaining to SEQ. ID. NO.: 1, the PatentIn software not being willing to accept this modification. The amino acid sequences in the attached paper copy and CRF copy are identical, as well as being identical to the CRF and papers copies in the parent application, and no new matter is presented.

The claims are re-presented in a format similar to the claims in the PCT counterpart application, PCT/US01/22051, (WO 02/03922), such claims having been indicated to meet conditions for patentability. New claims 1-2 correspond to claims 1-2 of the PCT application and claims 12-13 of the parent application. New claim 3 corresponds in substance to parent application claim 1. New claim 4 is similar to PCT application claim 3 and parent application claim 14. New claims 5-6 are similar to PCT claims 4-5, as narrowed to use of the claim 1 composition. New claim 7 is similar to PCT claim 7, as narrowed to use of the claim 1 composition. New claims 8-10 correspond to PCT claims 4-6. New claims 11-12 correspond to PCT claims 7-8. No new matter is presented.


2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Regular) or 37 CFR 1.153 (Design) Application
 - 13 Pages of specification
 - 2 Pages of claims
 - 1 Page of Abstract
3. Additional items enclosed
 - ☐ PTO 1449
 - ☒ Paper copy of Sequence Listing
 - ☒ Diskette with sequence listing
4. Declaration or oath
 - ☒ Enclosed executed by ☒ inventors.
5. Language ☒ English
6. Small Entity Statement(s) Applicant is entitled to and asserts small entity status.

7. Fee Payment Being Made At This Time

<input checked="" type="checkbox"/> basic filing fee (small entity)	385.00
0 claims over 20 @\$9	00.00
0 independent claims over 3	00.00
 TOTAL FEES	 \$385.00

8. Method of Payment of Fees

☒ A check in the amount of \$385.00 is enclosed.



John R. Casperson Reg. No. 28,198

John R. Casperson
PO Box 2174
Friendswood, Texas 77549

Tel. No. (281) 482-2961